Argos Therapeutics Inc  

(Public, NASDAQ:ARGS)   Watch this stock  
Find more results for ARGS
0.490
-0.238 (-32.66%)
Mar 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.48 - 0.70
52 week 0.48 - 13.97
Open 0.70
Vol / Avg. 2.37M/1.02M
Mkt cap 13.63M
P/E     -
Div/yield     -
EPS -1.87
Shares 41.36M
Beta 1.30
Inst. own 25%
Mar 27, 2017
Q4 2016 Argos Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -9383.31% -5608.65%
Operating margin -9598.39% -5532.29%
EBITD margin - -5353.18%
Return on average assets -59.80% -82.70%
Return on average equity -468.27% -
Employees 122 -
CDP Score - -

Address

4233 TECHNOLOGY DR
DURHAM, NC 27704-2173
United States - Map
+1-919-2876300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Officers and directors

Hubert Birner Ph.D. Independent Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Jeffrey D. Abbey President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Richard Katz M.D. Chief Financial Officer, Vice President
Age: 52
Bio & Compensation  - Reuters
Lori R. Harrelson Vice President - Finance
Age: 45
Bio & Compensation  - Reuters
John D. Menditto Vice President - Corporate Communications & Investor Relations
Bio & Compensation  - Reuters
Douglas C. Plessinger Vice President - Medical and Clinical Affairs
Age: 46
Bio & Compensation  - Reuters
Charles A. Nicolette Ph.D. Vice President - Research & Development, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Robert F. Carey Director
Age: 57
Bio & Compensation  - Reuters
Igor Krol Director
Bio & Compensation  - Reuters
Irackly Mtibelishvily Director
Bio & Compensation  - Reuters